Recent advances in chronic lymphocytic leukemia.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) was historically viewed as a slow-progressing disease with uniform treatment and prognosis.
• Advances in molecular diagnostics have significantly altered the understanding and management of CLL.
• Factors like B-cell receptor signaling, IGHV mutation status, and genetic aberrations influence CLL behavior.

Purpose of the Study:

• To highlight the impact of molecular discoveries on CLL management.
• To emphasize the necessity of early molecular variant diagnosis in CLL.
• To underscore the role of molecular profiling in predicting CLL prognosis and guiding therapy.

Main Methods:

• Review of current literature on CLL molecular pathophysiology.
• Analysis of the influence of molecular markers on treatment decisions.
• Evaluation of the prognostic significance of genetic aberrations in CLL.

Main Results:

• Molecular methods reveal significant heterogeneity in CLL, impacting disease progression.
• B-cell receptor response, IGHV mutation status, genetic aberrations, and apoptosis/proliferation defects are key determinants.
• These molecular variations necessitate a shift from standard treatment protocols.

Conclusions:

• The understanding of CLL has evolved from a monolithic disease to a molecularly diverse entity.
• Accurate molecular profiling is essential for tailoring therapy and predicting outcomes in CLL patients.
• Early identification of molecular variants is critical for optimizing patient management and prognosis in CLL.